|
|
| | ATM Inhibitor-7 Basic information |
| Product Name: | ATM Inhibitor-7 | | Synonyms: | ATM Inhibitor-7;1-Propanamine, N,N-dimethyl-3-[[5-[1-[(1R)-1-phenylethyl]-1H-1,2,3-triazolo[4,5-c]quinolin-8-yl]-2-pyridinyl]oxy]- | | CAS: | 3033712-80-7 | | MF: | C27H28N6O | | MW: | 452.55 | | EINECS: | | | Product Categories: | | | Mol File: | 3033712-80-7.mol |  |
| | ATM Inhibitor-7 Chemical Properties |
| Boiling point | 658.733±55.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.228±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | solubility | DMF: 10 mg/ml
DMSO: 10 mg/ml
Ethanol: 10 mg/mlPBS (pH 7.2): Slightly |
| | ATM Inhibitor-7 Usage And Synthesis |
| Uses | ATM Inhibitor-7 is a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor with an IC50 value of 1.0 nM. ATM Inhibitor-7 induces Apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11 (HY-16562). ATM Inhibitor-7 combines with CPT-11 shows antitumor activity[1]. | | in vivo | ATM Inhibitor-7 (5 mg/kg; i.p.; once daily for 23 days) combines with CPT-11 (5 mg/kg, i.p.; once a week) shows antitumor activity in mice[1]. | Animal Model: | Female nude mice (SW620 tumor xenograft model)[1] | | Dosage: | 5 mg/kg; CPT-11 (5 mg/kg, i.p.; once a week) | | Administration: | I.p.; once daily for 23 days | | Result: | Increased the antitumor activity of CPT-11. |
| | IC 50 | ATM: 1.0 nM (IC50) | | References | [1] Shiyu Zhang, et al. Discovery of [1,2,3]Triazolo[4,5-c]quinoline Derivatives as a New Class of Ataxia-Telangiectasia Mutated Kinase Inhibitors. ACS Med. Chem. Lett. 2023. |
| | ATM Inhibitor-7 Preparation Products And Raw materials |
|